Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 9, Issue 2, Pages -
Publisher
Springer Nature
Online
2018-01-19
DOI
10.1038/s41419-017-0039-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BCL-2 family proteins as regulators of mitochondria metabolism
- (2016) Atan Gross BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
- BCL-2 system analysis identifies high-risk colorectal cancer patients
- (2016) Andreas U Lindner et al. GUT
- The non-apoptotic action of Bcl-xL: regulating Ca2+ signaling and bioenergetics at the ER-mitochondrion interface
- (2016) Abasha Williams et al. JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation
- (2016) G. R. Anderson et al. Science Translational Medicine
- Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer
- (2015) C M Goodwin et al. CELL DEATH AND DIFFERENTIATION
- Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia
- (2015) M. I. Del Principe et al. HAEMATOLOGICA
- ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
- (2015) Shundong Cang et al. Journal of Hematology & Oncology
- An interconnected hierarchical model of cell death regulation by the BCL-2 family
- (2015) Hui-Chen Chen et al. NATURE CELL BIOLOGY
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
- (2015) A. N. Hata et al. Cancer Discovery
- Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin
- (2015) Zuzanna Baranski et al. Oncotarget
- Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia
- (2015) M. I. Del Principe et al. HAEMATOLOGICA
- Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation
- (2015) Ulrike Keitel et al. Oncotarget
- Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells
- (2014) S Colak et al. CELL DEATH AND DIFFERENTIATION
- Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings
- (2013) T. M. A. Abdel-Fatah et al. ANNALS OF ONCOLOGY
- Systems Analysis of BCL2 Protein Family Interactions Establishes a Model to Predict Responses to Chemotherapy
- (2013) A. U. Lindner et al. CANCER RESEARCH
- Bax Exists in a Dynamic Equilibrium between the Cytosol and Mitochondria to Control Apoptotic Priming
- (2013) Barbara Schellenberg et al. MOLECULAR CELL
- Structure-guided design of a selective BCL-XL inhibitor
- (2013) Guillaume Lessene et al. Nature Chemical Biology
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
- (2013) J. M. Balko et al. Cancer Discovery
- Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration
- (2012) Rhonda M. Perciavalle et al. NATURE CELL BIOLOGY
- An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
- (2011) S. Al-harbi et al. BLOOD
- Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol
- (2011) Frank Edlich et al. CELL
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase
- (2011) Kambiz N. Alavian et al. NATURE CELL BIOLOGY
- Breast Cancer Management: Opportunities and Barriers to an Individualized Approach
- (2011) E. A. Perez ONCOLOGIST
- BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
- (2010) S-J Dawson et al. BRITISH JOURNAL OF CANCER
- Chemotherapy for breast cancer (Review)
- (2010) Hassan ONCOLOGY REPORTS
- Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis
- (2009) G. Dewson et al. JOURNAL OF CELL SCIENCE
- Bcl-2 family proteins and cancer
- (2008) K W Yip et al. ONCOGENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started